

Reference number(s)

7131-A

Prior Authorization Criteria Brinsupri

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
|------------|--------------|
| Brinsupri | brensocatib |

Indications

FDA-approved Indications

Brinsupri

Brinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.

Coverage Criteria

Non-cystic fibrosis bronchiectasis (NCFB)

Authorization may be granted for the diagnosis of non-cystic fibrosis bronchiectasis (NCFB) in an adult or pediatric patient 12 years of age or older when the following criteria is met:

- The diagnosis was confirmed by a high-resolution computed tomography (HRCT) study of the chest.
- The patient has experienced a pulmonary exacerbation in the last 12 months (e.g., the presence of 3 or more of the following symptoms for at least 48 hours: increased cough; increased sputum production or change in sputum consistency; increased sputum purulence; increased

Brinsupri PA 7131-A P09-2025.docx

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

breathlessness, decreased exercise tolerance, or both; fatigue, malaise, or both; or hemoptysis.)

Continuation of Therapy

Non-cystic fibrosis bronchiectasis (NCFB)

Authorization may be granted for the diagnosis of non-cystic fibrosis bronchiectasis (NCFB) in an adult or pediatric patient 12 years of age when the following criteria is met:

• The patient has experienced a positive response to therapy (e.g., reduction in pulmonary exacerbations from baseline)

Duration of Approval (DOA)

• 7131-A: DOA: 12 months

References

- 1. Brinsupri [package insert]. Bridgewater, NJ: Insmed Incorporated; August 2025.
- 2. Lexicomp Online, Lexi-Drugs Online. Hudson, OH: UpToDate, Inc.; 2025; Accessed August 19, 2025.
- 3. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www.micromedexsolutions.com. Accessed August 19, 2025.
- 4. Barker AF, Karamooz E. Non-Cystic Fibrosis Bronchiectasis in Adults A Review. JAMA. 2025; 334(3): 253-264. doi: 10.1001/jama.2025.2680.
- 5. Imam JS, Duarte AG. Non-CF bronchiectasis: orphan disease no longer. Respiratory Medicine 2020;166: https://doi.org/10.1016/j.rmed.2020.105940.